Rising Prevalence of Cancer along with the Increasing Clinical Studies on Telomerase Reverse Transcriptase Product for the Treatment of Cancer are Factors Boosting the Market Growth

ABOUT THIS REPORT

OVERVIEW

Telomerase Reverse Transcriptase Market is expected to grow at a significant CAGR from 2020 to 2026.

Telomerase reverse transcriptase (TERT) is a catalytic subunit of the enzyme telomerase, together with the telomerase RNA component. Telomerase reverse transcriptase has been a useful therapeutic target in different studies of cancer.

The increasing incidence of cancer is the key driving factor of the market. For instance, according to the American Institute for Cancer Research, breast cancer is the second most common cancer globally.

According to the World Health Organization (WHO), globally, lung cancer accounts for 2.09 million cases in 2018. According to the American Cancer Society, in 2020, an estimated 228,820 new cases of lung cancer were diagnosed in the United States. According to the World Health Organization (WHO), every year, around 900,000 people worldwide are diagnosed with blood cancer. Globally, around 2 million new cases of breast cancer are diagnosed in 2018. Around 627,000 women died from breast cancer, which is approximately 15% of all cancer deaths among women in 2018. According to the World Health Organization (WHO), globally, colorectal cancer accounts for 1.80 million cases in 2018.

According to the American Cancer Society’s (ACS), in 2020, an estimate of 147,950 adults in the United States are expected to diagnose with colorectal cancer. According to the American Cancer Society, it is estimated that in 2020 there will be 191,930 new cases of prostate cancer and 33,330 deaths from prostate cancer in the United States.

ASTVAC-1, ASTVAC-2, ETS-2300, and Others is the type segment of the market scope. By application, the market is divided into Lung Cancer, Breast Cancer, Ovarian Cancer, and Others. The report covers value of the global market by type and application.

ASTVAC-2 might show significant growth in the coming years, owing to the collaboration between companies to develop ASTVAC-2 cancer vaccine and increasing clinical studies on ASTVAC-2 for cancer treatment.

North America, Europe, Asia Pacific, South America, and Middle East & Africa are taken into consideration at the global telomerase reverse transcriptase value figures. While North America is further categorized into enhancing the United States, Canada, and Mexico, Europe is split into the United Kingdom, Germany, France, Italy, and Rest of Europe. Asia-Pacific covers India, China, Japan, South Korea, and Rest of Asia Pacific in its scope. South America is bifurcated into Brazil, Argentina, and Rest of South America, with Middle East & Africa involving GCC Countries, Egypt, South Africa, and Rest of Middle East & Africa.

North America is expected to dominate the telomerase reverse transcriptase market in the coming years, due to the rising prevalence of cancer. According to the American Cancer Society, in 2020, an estimated 1.8 million new cancer cases will be diagnosed and 606,520 cancer deaths in the United States. Moreover, rising clinical studies for cancer treatment and increasing investment by companies and government organizations for the treatment of cancer are some of the factors that are boosting the North America telomerase reverse transcriptase market.

Major players operating in the telomerase reverse transcriptase industry include F. Hoffmann-La Roche Ltd, Asterias Biotherapeutics Inc, Johnson & Johnson, Inovio Pharmaceuticals Inc, e-Therapeutics Plc, Invectys SA, Komipharm International Co Ltd, Telocyte LLC, Mediolanum farmaceutici SpA, Argos Therapeutics Inc, Vaxon Biotech, TILT Biotherapeutics Ltd, and Ultimovacs AS.

The companies are increasing development of telomerase reverse transcriptase for the treatment of cancer, increasing clinical trials for telomerase reverse transcriptase and companies are jointly researching telomerase reverse transcriptase for the treatment of cancer are some of the strategies adopted by the major companies.